Brain-derived neurotrophic factor levels and depression during methamphetamine withdrawal.

Area of Science:

• Neuroscience
• Psychiatry
• Addiction Medicine

Background:

• Depression symptoms frequently co-occur with methamphetamine (METH) dependence.
• Brain-derived neurotrophic factor (BDNF) is implicated in both depression pathophysiology and METH dependence.

Purpose of the Study:

• To investigate the role of BDNF in the development of depression symptoms during METH withdrawal.

Main Methods:

• 179 METH-dependent patients were recruited, with 131 completing a two-week follow-up.
• Serum BDNF levels were measured using ELISA.
• Depression and withdrawal symptoms were assessed using the Beck Depression Inventory (BDI) and Amphetamine Withdrawal Questionnaire (AWQ).

Main Results:

• 48.9% of patients developed depression symptoms by the two-week endpoint.
• Patients with depression symptoms had significantly lower serum BDNF levels.
• Serum BDNF levels ≤ 1251.0 pg/ml were independently associated with a higher risk of developing depression symptoms (OR = 3.50, p = 0.028).

Conclusions:

• Lower serum BDNF levels are associated with an increased risk of depression symptoms during METH withdrawal.
• BDNF may serve as a potential biomarker for predicting depression in this population.